The Natural History of Congenital X-Linked Retinoschisis and Conversion between Phenotypes over Time.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 05 2018
revised: 15 08 2018
accepted: 16 08 2018
entrez: 3 4 2019
pubmed: 3 4 2019
medline: 18 12 2019
Statut: ppublish

Résumé

To evaluate the natural history of congenital X-linked retinoschisis (CXLRS) and to assess disease stability or progression over time. Retrospective case series at a single-center, tertiary care, pediatric retina practice. One hundred two eyes of 51 patients with CXLRS. The clinical examinations, fundus photographs, and OCT images of all patients with CXLRS were assessed. Eyes that initially demonstrated combined retinoschisis-retinal detachments and those with large, centrally overhanging schisis cavities were excluded from the analysis (n = 49) because they underwent surgery, which precluded observation of the natural disease course. Stability or conversion of CXLRS phenotype over time. Fifty-three eyes met inclusion criteria for observation of natural disease history over time. At the time of diagnosis, 7.5% of eyes showed type 1 disease (n = 4), 17% showed type 2 disease (n = 9), 66% showed type 3 disease (n = 35), and 9.5% showed type 4 disease (n = 5). Mean length of follow-up was 7.4 years. A total of 7.5% of eyes demonstrated a combined retinoschisis-retinal detachment requiring surgery (n = 4), whereas 1.8% demonstrated a large, centrally overhanging schisis cavity requiring surgery (n = 1). Overall, 83% of eyes (n = 44) remained the same type without conversion or development of a complication requiring surgery. The remaining 17% of eyes (n = 9) experienced some type of change from their baseline diagnosis, with 7.5% (n = 4) converting between phenotypes and 9.5% (n = 5) demonstrating a complication requiring surgery; 3.75% of eyes (n = 2) converted from type 2 to 3 and 7.5% of eyes (n = 4) converted from type 3 to a combined retinoschisis-retinal detachment with mean time to conversion of 4.07 years. This longitudinal study conveyed the natural history of CXLRS. Congenital X-linked retinoschisis displayed long-term stability in 83% of eyes with conversion or progression of the disease to a more severe phenotype in the remaining cases. Type 3 CXLRS was a risk factor for the development of a combined retinoschisis-retinal detachment and may benefit from closer follow-up.

Identifiants

pubmed: 30935660
pii: S2468-6530(18)30332-4
doi: 10.1016/j.oret.2018.08.006
pii:
doi:

Substances chimiques

Eye Proteins 0
RS1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-82

Informations de copyright

Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Edward H Wood (EH)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan.

Itsara Lertjirachai (I)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan; Department of Ophthalmology, Srinakharinwirot University, Bangkok, Thailand.

Benjamin K Ghiam (BK)

William Beaumont School of Medicine, Oakland University, Rochester, Michigan.

Nicole Koulisis (N)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan; USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Stavros N Moysidis (SN)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan.

Ali Dirani (A)

Centre Universitaire d' Ophtalmologie, CHU de Québec-Université Laval, Quebec City, Canada.

Kimberly A Drenser (KA)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan; William Beaumont School of Medicine, Oakland University, Rochester, Michigan.

Antonio Capone (A)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan; William Beaumont School of Medicine, Oakland University, Rochester, Michigan.

Michael T Trese (MT)

Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan; William Beaumont School of Medicine, Oakland University, Rochester, Michigan. Electronic address: mgjt46@aol.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH